TP53 alterations have been reported in 29–80% of ovarian tumors, with a higher incidence in high-grade pelvic (primary ovarian, tubal, or peritoneal) serous carcinoma (91–97%) (33). This evidence concerns the gene TP53 and ovarian neoplasm.